Related Experiment Video

Updated: Jun 3, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Statins: cardiovascular risk reduction in percutaneous coronary intervention-basic and clinical evidence of

Enrique C Morales-Villegas1, Germano Di Sciascio, Carlo Briguori

  • 1Centro de Investigación Cardiometabólica, Quinta Avenida 702-210, Frac. Agricultura, Aguascalientes, 20234 México, AGS, Mexico.

International Journal of Hypertension
|April 5, 2011
PubMed

Insights

Statins significantly reduce cardiovascular events and prolong life by lowering LDL-cholesterol and providing "pharmacological myocardial preconditioning" before ischemia. This review explores their hyperacute use in coronary syndromes undergoing percutaneous coronary intervention.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Statins exert lipid and non-lipid effects via LDL-cholesterol reduction, GTPase isoprenylation inhibition, and myocyte-protective enzyme activation.
  • While reduced LDL-cholesterol, inflammation biomarkers, and atheroregression are surrogate markers, the ultimate benefit of statins lies in decreasing cardiovascular events.
  • Statins are uniquely effective in reducing cardiovascular event incidence and prolonging life across diverse clinical scenarios.

Purpose of the Study:

  • To review evidence supporting a novel indication for HMG-CoA reductase inhibitors (statins).
  • To explore the concept of "pharmacological myocardial preconditioning" using hyperacute statin therapy.
  • To examine the efficacy of pre-procedural statin use in patients with coronary syndromes undergoing percutaneous coronary intervention.

Main Methods:

  • Review of basic and clinical evidence from multiple trials.
  • Analysis of studies investigating statin mechanisms of action.
  • Examination of data from ARMYDA-Original, NAPLES I-II, ARMYDA-ACS, ARMYDA-RECAPTURE, Non-STEMI-Korean, and Korean-STEMI trials.

Main Results:

  • Statins demonstrably reduce cardiovascular events and improve survival.
  • Pharmacological myocardial preconditioning via hyperacute statin use is supported by clinical evidence.
  • Pre-procedural statin administration in acute coronary syndromes undergoing PCI shows significant benefits.

Conclusions:

  • HMG-CoA reductase inhibitors offer a new indication as "pharmacological myocardial preconditioning" before anticipated ischemia.
  • Hyperacute statin use is a valuable strategy for patients with coronary syndromes undergoing percutaneous coronary intervention.
  • Statins provide crucial cardioprotection, reducing cardiovascular events and mortality in various settings.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...